Search

Your search keyword '"Caro-Teller JM"' showing total 2 results
Start Over Author "Caro-Teller JM" Topic cytokine release syndrome
2 results on '"Caro-Teller JM"'

1. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.

Author

de la Calle C, López-Medrano F, Pablos JL, Lora-Tamayo J, Maestro-de la Calle G, Sánchez-Fernández M, Fernández-Ruiz M, Pérez-Jacoiste Asín MA, Caro-Teller JM, García-García R, Catalán M, Martínez-López J, Sevillano Á, Origüen J, Ripoll M, San Juan R, Lalueza A, de Miguel B, Carretero O, Aguilar F, Gómez C, Paz-Artal E, Bueno H, Lumbreras C, and Aguado JM

Subjects
Aged, COVID-19 complications, Case-Control Studies, Cohort Studies, Cytokine Release Syndrome etiology, Female, Hospital Mortality, Humans, Immunomodulation drug effects, Male, Middle Aged, Retrospective Studies, Salvage Therapy, Spain epidemiology, Treatment Failure, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Cytokine Release Syndrome drug therapy, Interleukin 1 Receptor Antagonist Protein therapeutic use, SARS-CoV-2, COVID-19 Drug Treatment
Abstract

Objectives: A subgroup of patients with SARS-CoV-2 infection was thought to have developed cytokine release syndrome and were treated with tocilizumab; however, a significant percentage of patients evolved. This study aimed to determine the usefulness of anakinra as a rescue treatment for patients with tocilizumab-refractory COVID-19 disease., Methods: A prospective cohort of patients with COVID-19 pneumonia who received anakinra as salvage therapy after failure of tocilizumab were compared (1:1) with selected controls in a historical cohort of patients treated with tocilizumab. Cases and controls were matched by age, comorbidities, pulse oximetry oxygen saturation to fraction of inspired oxygen (SpO2/FiO2) ratio at baseline, and time elapsed since the initiation of treatment with tocilizumab. The primary outcome was the improvement in clinical status measured by a 6-point ordinal scale, from baseline to day 21., Results: The study included 20 cases and 20 controls (mean age 65.3 ± 12.8 years, 65% males). No differences were found in the clinical improvement rates at 7, 14 and 21 days of follow-up. The in-hospital mortality rate for patients receiving anakinra was 55% vs. 45% in the control group (P = 0.527)., Conclusions: Treatment with anakinra was not useful in improving the prognosis of patients with tocilizumab-refractory severe COVID-19., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Published
2021
Full Text
View/download PDF

2. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.

Author

Fernández-Ruiz M, López-Medrano F, Pérez-Jacoiste Asín MA, Maestro de la Calle G, Bueno H, Caro-Teller JM, Catalán M, de la Calle C, García-García R, Gómez C, Laguna-Goya R, Lizasoáin M, Martínez-López J, Origüen J, Pablos JL, Ripoll M, San Juan R, Trujillo H, Lumbreras C, and Aguado JM

Subjects
Administration, Intravenous, Adult, Body Temperature drug effects, C-Reactive Protein metabolism, COVID-19 immunology, COVID-19 mortality, COVID-19 virology, Cytokine Release Syndrome immunology, Cytokine Release Syndrome mortality, Cytokine Release Syndrome virology, Female, Heart Rate drug effects, Humans, Interferon-beta adverse effects, L-Lactate Dehydrogenase blood, Male, Middle Aged, Receptors, Interleukin-6 antagonists & inhibitors, Receptors, Interleukin-6 genetics, Receptors, Interleukin-6 immunology, Respiratory Rate drug effects, Retrospective Studies, SARS-CoV-2 immunology, Severity of Illness Index, Survival Analysis, Antibodies, Monoclonal, Humanized therapeutic use, Antiviral Agents therapeutic use, Cytokine Release Syndrome prevention & control, Immunologic Factors therapeutic use, SARS-CoV-2 pathogenicity, COVID-19 Drug Treatment
Abstract

Coronavirus disease 2019 (COVID-19) can lead to a massive cytokine release. The use of the anti-interleukin-6 receptor monoclonal antibody tocilizumab (TCZ) has been proposed in this hyperinflammatory phase, although supporting evidence is limited. We retrospectively analyzed 88 consecutive patients with COVID-19 pneumonia that received at least one dose of intravenous TCZ in our institution between 16 and 27 March 2020. Clinical status from day 0 (first TCZ dose) through day 14 was assessed by a 6-point ordinal scale. The primary outcome was clinical improvement (hospital discharge and/or a decrease of ≥2 points on the 6-point scale) by day 7. Secondary outcomes included clinical improvement by day 14 and dynamics of vital signs and laboratory values. Rates of clinical improvement by days 7 and 14 were 44.3% (39/88) and 73.9% (65/88). Previous or concomitant receipt of subcutaneous interferon-β (adjusted odds ratio [aOR]: 0.23; 95% confidence interval [CI]: 0.06-0.94; P = .041) and serum lactate dehydrogenase more than 450 U/L at day 0 (aOR: 0.25; 95% CI: 0.06-0.99; P = .048) were negatively associated with clinical improvement by day 7. All-cause mortality was 6.8% (6/88). Body temperature and respiratory and cardiac rates significantly decreased by day 1 compared to day 0. Lymphocyte count and pulse oximetry oxygen saturation/FiO 2 ratio increased by days 3 and 5, whereas C-reactive protein levels dropped by day 2. There were no TCZ-attributable adverse events. In this observational single-center study, TCZ appeared to be useful and safe as immunomodulatory therapy for severe COVID-19 pneumonia., (© 2020 Wiley Periodicals LLC.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results